Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

Yamazaki, K.; Nagase, M.; Tamagawa, H.; Ueda, S.; Tamura, T.; Murata, K.; Eguchi Nakajima, T.; Baba, E.; Tsuda, M.; Moriwaki, T.; Esaki, T.; Tsuji, Y.; Muro, K.; Taira, K.; Denda, T.; Funai, S.; Shinozaki, K.; Yamashita, H.; Sugimoto, N.; Okuno, T.; Nishina, T.; Umeki, M.; Kurimoto, T.; Takayama, T.; Tsuji, A.; Yoshida, M.; Hosokawa, A.; Shibata, Y.; Suyama, K.; Okabe, M.; Suzuki, K.; Seki, N.; Kawakami, K.; Sato, M.; Fujikawa, K.; Hirashima, T.; Shimura, T.; Taku, K.; Otsuji, T.; Tamura, F.; Shinozaki, E.; Nakashima, K.; Hara, H.; Tsushima, T.; Ando, M.; Morita, S.; Boku, N.; Hyodo, I.

Published in

Elsevier, Annals of Oncology, 8(27), p. 1539-1546, 2016

DOI: 10.1093/annonc/mdw206

Tools

Export citation

Search in Google Scholar

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)

Journal article published in 2016 by K. Yamazaki, M. Nagase, H. Tamagawa, S. Ueda, T. Tamura, K. Murata, T. Eguchi Nakajima, E. Baba, M. Tsuda, T. Moriwaki, T. Esaki, Y. Tsuji, K. Muro, K. Taira, T. Denda and other authors.

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving restricted

Upload

Published version: archiving forbidden

Policy details

Data provided by

Published in

Links

Tools

Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G)